This latter work [51] demonstrated that FGFR2 serves as a scaffold for regulation of NFκB signaling and showed, much as is the case for FGFR4 [31], that FGFR2 expression reduces STAT3 phosphorylation, nuclear RelA/p65 NFκB translocation, and expression of NFκB-dependent transcripts such as interleukin-6, leading overall to reduced breast cancer cell proliferation/invasiveness. The gene discussed is STAT3; the disease is breast carcinoma.